Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial

Oncologist - United States
doi 10.1634/theoncologist.2018-0839
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Pathology and Oncology Research
MedicineForensic MedicinePathologyOncologyCancer Research
2020English

Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2015English

Cost-Effectiveness Analysis of Sunitinib Versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore

International Journal of Technology Assessment in Health Care
Health Policy
2019English

Cost-Effectiveness and Cost-Utility Analysis of Sunitinib Versus Sorafenib and Bevacizumab + Interferon-Alfa as First-Line Treatment for Metastatic Renal Cell Carcinoma in Ecuador

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

Hypertension as Predictor of Sunitinib Treatment Outcome in Metastatic Renal Cell Carcinoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2011English

Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-Induced Hypertension in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2017English

A Phase I/Ii Trial of BNC105P With Everolimus in Metastatic Renal Cell Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2015English

OA13.03 Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Double-Blind Phase 2 Trial

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy